Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of SNIPR001 in healthy subjects
NCT05277350Phase 1Completed
- Sponsor
- SNIPR Biome
- Start
- Mar 2022
- Primary completion
- Nov 2022
- Modality
- CRISPR-Cas9, Gene Silencing, Single Strain Products
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SNIPR001 in Escherichia coli infection and bloodstream infection (BSI) (3 cohorts), sponsored by SNIPR Biome. Primary endpoint: Incidence and severity of Adverse Events (AEs) and Medically Attended Adverse Events (MAAEs) at Day 35. Started Mar 2022; status: completed.
02
Drugs
SNIPR001
03
Conditions
Escherichia coli infectionbloodstream infection (BSI)
Beyond the preview
Go deeper on NCT05277350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05277350.